[1] Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer[J]. Nat Rev Cancer, 2015, 15(6): 321-333. [2] Zhou P, Jiang N, Zhang GX, et al. MiR-203 inhibits tumor invasion and metastasis in gastric cancer by ATM[J]. Acta Biochim Biophys Sin (Shanghai), 2016, 48(8): 696-703. [3] Yang CH, Wang Y, Sims M, et al. MicroRNA203a suppresses glioma tumorigenesis through an ATM-dependent interferon response pathway[J]. Oncotarget, 2017, 8(68): 112980-112991. [4] Wang L, Tong D, Guo Q, et al. HOXD3 targeted by miR-203a suppresses cell metastasis and angiogenesis through VEGFR in human hepatocellular carcinoma cells[J]. Sci Rep, 2018, 8(1): 2431-2441. [5] 吴晓斌, 许红英, 徐 慧. miR-203a-3p通过靶向PRMT5抑制胃癌细胞增殖[J]. 现代肿瘤医学, 2017, 25(14): 2226-2230. [6] Na XY, Shang XS, Zhao Y, et al. MiR-203a functions as a tumor suppressor in bladder cancer by targeting SIX4[J]. Neoplasma, 2019, 66(2): 211-221. [7] Gomes BC, Martins M, Lopes P, et al. Prognostic value of microRNA-203a expression in breast cancer[J]. Oncol Rep, 2016, 36(3): 1748-1756. [8] Jin MH, Oh DY. ATM in DNA repair in cancer[J]. Pharmacol Ther, 2019, 203: 107391. [9] Bartkova J, Horejsí Z, Koed K, et al. Damage response as a candidate anti-cancer barrier in early human tumorigenesis[J]. Nature, 2005, 434(7035): 864-870. [10] Hsia SM, Yu CC, Shih YH, et al. Isoliquiritigenin as a cause of DNA damage and inhibitor of ataxia-telangiectasia mutated expression leading to G2/M phase arrest and apoptosis in oral squamous cell carcinoma[J]. Head Neck, 2016, 38(Suppl 1): E360-371. [11] Choi M, Kipps T, Kurzrock R.ATM mutations in cancer: Therapeutic implications[J]. Mol Cancer Ther, 2016, 15(8): 1781-1791. [12] 刘显荣, 卢先州. ATM基因与胰腺导管腺癌发病及放疗增敏研究进展[J].现代临床医学, 2018, 44(1): 5-8. [13] Rondeau S, Vacher S, De Koning L, et al. ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels[J]. Br J Cancer, 2015, 112(6): 1059-1066. [14] Liu HY, Zhang YY, Zhu BL, et al. MiR-203a-3p regulates the biological behaviors of ovarian cancer cells through mediating the Akt/GSK-3β/Snail signaling pathway by targeting ATM[J]. J Ovarian Res, 2019, 12(1): 60-72. [15] Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): e279-289. [16] 乳腺癌诊疗规范(2011年版)[J].中国实用外科杂志, 2011, 31(10): 902-907. [17] Cai KT, Feng CX, Zhao JC, et al. Upregulated miR 203a 3p and its potential molecular mechanism in breast cancer: A study based on bioinformatics analyses and a comprehensive meta analysis[J]. Mol Med Rep, 2018,18(6): 4994-5008. [18] Bueno RC, Canevari RA, Villacis RA, et al. ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas[J]. Ann Oncol, 2014, 25(1): 69-75. [19] 郎 磊. ATM对乳腺癌细胞迁移和侵袭影响及其机制研究[D]. 重庆: 重庆医科大学, 2017. [20] Zhang Z, Zhang B, Li W, et al. Epigenetic silencing of miR-203 upregulates SNAI2 andcontributes to the invasiveness of malignant breast cancer cells[J]. Genes Cancer, 2011, 2(8): 782-791. [21] Sun M, Guo X, Qian X, et al. Activation of the ATM-Snail pathway promotes breast cancer metastasis[J]. J Mol Cell Biol, 2012, 4(5): 304-315. |